This study is part of the EAVE II project. EAVE II is funded by the MRC (MC_PC_19075) with the support of BREATHE—The Health Data Research Hub for Respiratory Health (MC_PC_19004), which is funded through the UK Research and Innovation Industrial Strategy Challenge Fund and delivered through the Health Data Research UK. This research is part of the Data and Connectivity National Core Study, led by Health Data Research UK in partnership with the Office for National Statistics and funded by UK Research and Innovation (grant ref MC_PC_20058). This work was also supported by The Alan Turing Institute via ‘Towards Turing 2.0’ EPSRC Grant Funding. Additional support has been provided through Public Health Scotland, the Scottish Government Directo...
Introduction: The novel coronavirus SARS-CoV-2, which emerged in December 2019, has caused millions ...
Background: The BNT162b2 mRNA (Pfizer–BioNTech) and ChAdOx1 nCoV-19 (Oxford–AstraZeneca) COVID-19 v...
BACKGROUND: BNT162b2 mRNA and ChAdOx1 nCOV-19 adenoviral vector vaccines have been rapidly rolled ou...
Funding: This study is part of the EAVE II project. EAVE II is funded by the MRC (MC_PC_19075) with ...
Background: The two-dose BNT162b2 (Pfizer-BioNTech) vaccine has demonstrated high efficacy against C...
Funding: This research is part of the Data and Connectivity National Core Study, led by Health Data ...
EAVE II is supported by the Medical Research Council (MR/R008345/1) with the support of BREATHE – Th...
This study is part of the EAVE II project. EAVE II is funded by the MRC (MC_PC_19075) with the suppo...
BackgroundThe dynamics of acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission and sev...
EAVE II is funded by the Medical Research Council (MR/R008345/1) with the support of BREATHE—The Hea...
Funding: This research is part of the Data and Connectivity National Core Study, led by Health Data ...
This work was funded by the National Core Studies–Immunity group. This research is part of the Data ...
Background: We aimed to explore the effectiveness of one-dose BNT162b2 vaccination upon SARS-CoV-2 i...
Background: Several SARS-CoV-2 vaccines have been shown to provide protection against COVID-19 hosp...
EAVE II is funded by the Medical Research Council (MC_PC_19075) with the support of BREATHE: the Hea...
Introduction: The novel coronavirus SARS-CoV-2, which emerged in December 2019, has caused millions ...
Background: The BNT162b2 mRNA (Pfizer–BioNTech) and ChAdOx1 nCoV-19 (Oxford–AstraZeneca) COVID-19 v...
BACKGROUND: BNT162b2 mRNA and ChAdOx1 nCOV-19 adenoviral vector vaccines have been rapidly rolled ou...
Funding: This study is part of the EAVE II project. EAVE II is funded by the MRC (MC_PC_19075) with ...
Background: The two-dose BNT162b2 (Pfizer-BioNTech) vaccine has demonstrated high efficacy against C...
Funding: This research is part of the Data and Connectivity National Core Study, led by Health Data ...
EAVE II is supported by the Medical Research Council (MR/R008345/1) with the support of BREATHE – Th...
This study is part of the EAVE II project. EAVE II is funded by the MRC (MC_PC_19075) with the suppo...
BackgroundThe dynamics of acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission and sev...
EAVE II is funded by the Medical Research Council (MR/R008345/1) with the support of BREATHE—The Hea...
Funding: This research is part of the Data and Connectivity National Core Study, led by Health Data ...
This work was funded by the National Core Studies–Immunity group. This research is part of the Data ...
Background: We aimed to explore the effectiveness of one-dose BNT162b2 vaccination upon SARS-CoV-2 i...
Background: Several SARS-CoV-2 vaccines have been shown to provide protection against COVID-19 hosp...
EAVE II is funded by the Medical Research Council (MC_PC_19075) with the support of BREATHE: the Hea...
Introduction: The novel coronavirus SARS-CoV-2, which emerged in December 2019, has caused millions ...
Background: The BNT162b2 mRNA (Pfizer–BioNTech) and ChAdOx1 nCoV-19 (Oxford–AstraZeneca) COVID-19 v...
BACKGROUND: BNT162b2 mRNA and ChAdOx1 nCOV-19 adenoviral vector vaccines have been rapidly rolled ou...